ClinicalTrials.gg
CompletedNCT07312851Updated Jul 9, 2026

A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants

A Phase 1 interventional study of Andexanet alfa and Rivaroxaban in Healthy Participants, sponsored by AstraZeneca. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
191
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to characterize andexanet posology and interaction between andexanet and enoxaparin post infusion in healthy participants.

Read the detailed description

This is a single-blind, placebo-controlled study. The study has 4 modules, which is then divided into 2 parts. Part A of the study will focus on further characterization of andexanet posology and Part B of the study will evaluate a re-institution of anticoagulation with enoxaparin.

Module 1, 2 and 4 - rivaroxaban, apixaban and enoxaparin: These modules are designed to determine the pharmacodynamic (PD) effect of andexanet by assessing its reversal effects on rivaroxaban and apixaban anticoagulation, or assessing its effects in the absence of anticoagulants, and to identify the time interval after andexanet administration at which andexanet shows no impact on enoxaparin.

Module 3 - rivaroxaban and apixaban: This Module is designed to determine the PD effect of bolus only andexanet by assessing its reversal effect on rivaroxaban and apixaban anticoagulation.

All the Modules will comprise:

  • A Screening/Enrollment Period of maximum 28 days.
  • An in-house stay comprising of a safety baseline lab period (Day -3 to Day -1)
  • Treatment period (Day 1 to Day 2)
  • Safety follow-up period (Day 3 to Day 5)
  • A final Follow-up Visit within 30 days (+7 days) after the last andexanet/placebo administration.
02

Conditions studied

  • Healthy Participants

Keywords

  • Posology
  • Re-anticoagulation
  • Pharmacodynamics
  • Life-threatening or uncontrolled bleeding
  • Thrombotic events
  • Factor Xa inhibitors
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main Inclusion Criteria:

  • All females must have a negative pregnancy test at the Screening Visit.
  • Females of must not be lactating and if heterosexually active must agree to use an approved method of highly effective .
  • Sexually active fertile male participants with partners of childbearing potential must adhere to the study specific contraception methods.
  • Have a (BMI) between 18.5 and 30.0 kg/m2 (both inclusive) and weigh at least 60 kg.
  • Agree to abstain from alcohol consumption or smoking for the duration of the residential period, and from the use of drugs of abuse for the duration of the study.
  • Be in good health and agree to have any dietary or nutritional supplements, if needed.

Main Exclusion Criteria:

  • History of any disease or disorder which may either put the participant at risk because of participation in the study or influence the results or the participant's ability to participate in the study.
  • History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • History of abnormal bleeding or bleeding disorders (eg, hemophilia, von Willebrand disease), signs or symptoms of active bleeding, or risk factors for bleeding.
  • History of adult asthma or or current regular or as needed use of inhaled medications.
  • Family history of or known risk factors for a hypercoagulable or thrombotic condition or thrombotic event, such as anti-phospholipid syndrome; Factor V Leiden carrier or homozygote; Protein C, S, or AT3 activity below the normal range.
  • Past or current medical history of thrombosis, any sign or symptom that suggests an increased risk of a systemic thrombotic condition, or recent events that may increase risk of thrombosis.
  • Any medical or surgical conditions which may impair drug (anticoagulant or andexanet) uptake, metabolism, or excretion.
  • An absolute or relative to anticoagulation or treatment with apixaban, rivaroxaban or enoxaparin.
  • Any clinically significant illness or medical procedure within 4 weeks of the first administration of study intervention.
  • Any clinically significant abnormalities in clinical chemistry, hematology, coagulation or urinalysis results
  • Any positive result on Screening for serum surface antigen (HBsAg) OR anti-hepatitis B core (HBc) antibody, indicative of active hepatitis B (ie, participants with positive anti-HBc antibody result are acceptable if anti-HBc IgM antibodies are negative), anti- virus (HCV) or (HIV).
  • History of severe allergy/ or ongoing clinically significant allergy/hypersensitivity, including heparin-induced thrombocytopenia, or history of hypersensitivity to drugs with a similar chemical structure or class to andexanet, apixaban, rivaroxaban, or enoxaparin or any of the vehicle ingredients.
  • Use of any prescribed or nonprescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, intake of > 3 × daily recommended levels of vitamins and minerals during the 2 weeks prior to the first administration of study intervention or longer (> 5 half-lives) if the medication has a long half-life. The participant has taken (by any route) one or more doses of aspirin (including baby aspirin), salicylate or subsalicylate, other antiplatelet drugs (eg, ticagrelor, clopidogrel, ticlopidine), non-steroidal anti-inflammatory drugs, fibrinolytic, or any anticoagulant within 7 days prior to Admission or is anticipated to require such drugs during the study. The participant has been receiving (by any route) hormonal contraception, HRT (including over-the-counter products), or testosterone during the 4 weeks prior to Admission or is anticipated to require such drugs during the study.
  • Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 30 days or 5 half-lives (whichever is longest) of Admission.
  • Participants who have previously received andexanet.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
191 participants (actual)

Study arms

  • Experimental
    Module 1: Rivaroxaban + Andexanet (dose A)

    Participants will receive once daily dose of 20 mg rivaroxaban from Day -3 to Day -1 to achieve steady state plasma levels. On Day 1, approximately 3 hours before andexanet (dose A) dosing, the participants will receive an additional dose of rivaroxaban. Participants will be further allocated to groups to receive doses of enoxaparin at different time points after the end of andexanet bolus.

    Drug: Andexanet alfa · Drug: Rivaroxaban · Drug: Enoxaparin

  • Experimental
    Module 1: Rivaroxaban + Andexanet (dose B)

    Participants will receive once daily dose of 20 mg rivaroxaban from Day -3 to Day -1 to achieve steady state plasma levels. On Day 1, approximately 3 hours before andexanet (dose B) dosing, the participants will receive an additional dose of rivaroxaban.

    Drug: Andexanet alfa · Drug: Rivaroxaban

  • Experimental
    Module 1: Rivaroxaban + Andexanet (dose C)

    Participants will receive once daily dose of 20 mg rivaroxaban from Day -3 to Day -1 to achieve steady state plasma levels. On Day 1, approximately 3 hours before andexanet (dose C) dosing, the participants will receive an additional dose of rivaroxaban.

    Drug: Andexanet alfa · Drug: Rivaroxaban

  • Experimental
    Module 1: Rivaroxaban + Placebo

    Participants will receive once daily dose of 20 mg rivaroxaban from Day -3 to Day -1 to achieve steady state plasma levels. On Day 1, approximately 3 hours before placebo (equivalent to dose B of andexanet) dosing, the participants will receive an additional dose of rivaroxaban. Participants will be further allocated to groups to receive doses of enoxaparin at different time points after placebo administration.

    Drug: Rivaroxaban · Drug: Enoxaparin · Other: Placebo

  • Experimental
    Module 2: Apixaban + Andexanet (dose B)

    Participants will receive twice daily dose of 5 mg apixaban from Day -3 to Day -1 to achieve steady state plasma levels. On Day 1, approximately 3 hours before andexanet (dose B) dosing, the participants will receive an additional dose of apixaban. Participants will be further allocated to groups to receive doses of enoxaparin at different time points after the end of andexanet bolus.

    Drug: Andexanet alfa · Drug: Apixaban · Drug: Enoxaparin

  • Experimental
    Module 2: Apixaban + Andexanet (dose C)

    Participants will receive twice daily dose of 5 mg apixaban from Day -3 to Day -1 to achieve steady state plasma levels. On Day 1, approximately 3 hours before andexanet (dose C) dosing, the participants will receive an additional dose of apixaban.

    Drug: Andexanet alfa · Drug: Apixaban

  • Experimental
    Module 2: Apixaban + Andexanet (dose D)

    Participants will receive twice daily dose of 5 mg apixaban from Day -3 to Day -1 to achieve steady state plasma levels. On Day 1, approximately 3 hours before andexanet (dose D) dosing, the participants will receive an additional dose of apixaban.

    Drug: Andexanet alfa · Drug: Apixaban

  • Experimental
    Module 2: Apixaban + Placebo

    Participants will receive twice daily dose of 5 mg apixaban from Day -3 to Day -1 to achieve steady state plasma levels. On Day 1, approximately 3 hours before placebo (equivalent to dose B of andexanet) dosing, the participants will receive an additional dose of apixaban. Participants will be further allocated to groups to receive doses of enoxaparin at different time points after placebo administration.

    Drug: Apixaban · Drug: Enoxaparin · Other: Placebo

  • Experimental
    Module 3: Rivaroxaban + Andexanet (Dose A)

    Participants will receive once daily dose of 20 mg rivaroxaban from Day -3 to Day -1 to achieve steady state plasma levels. On Day 1, approximately 3 hours before andexanet (dose A) dosing, the participants will receive an additional dose of rivaroxaban.

    Drug: Andexanet alfa · Drug: Rivaroxaban

  • Experimental
    Module 3: Apixaban + Andexanet (Dose B)

    Participants will receive twice daily dose of 5 mg apixaban from Day -3 to Day -1 to achieve steady state plasma levels. On Day 1, approximately 3 hours before andexanet (dose B) dosing, the participants will receive an additional dose of apixaban.

    Drug: Andexanet alfa · Drug: Apixaban

  • Experimental
    Module 3: Rivaroxaban + Placebo

    Participants will receive once daily dose of 20 mg rivaroxaban from Day -3 to Day -1 to achieve steady state plasma levels. On Day 1, approximately 3 hours before placebo (equivalent to dose A of andexanet) dosing, the participants will receive an additional dose of rivaroxaban.

    Drug: Rivaroxaban · Other: Placebo

  • Experimental
    Module 3: Apixaban + Placebo

    Participants will receive twice daily dose of 5 mg apixaban from Day -3 to Day -1 to achieve steady state plasma levels. On Day 1, approximately 3 hours before placebo (equivalent to dose B of andexanet) dosing, the participants will receive an additional dose of apixaban.

    Drug: Apixaban · Other: Placebo

  • Experimental
    Module 4: Placebo + Andexanet (dose C)

    Participants will receive daily dose of one placebo tablet from Day -3 to Day -1. On Day 1, approximately 3 hours before andexanet (dose C) dosing, the participants will receive an additional placebo tablet.

    Drug: Andexanet alfa · Other: Placebo

  • Experimental
    Module 4: Placebo + Andexanet (dose B)

    Participants will receive daily dose of one placebo tablet from Day -3 to Day -1. On Day 1, approximately 3 hours before andexanet (dose B) dosing, the participants will receive an additional placebo tablet. Participants will be further allocated to groups to receive doses of enoxaparin at different time points after the end of andexanet bolus.

    Drug: Andexanet alfa · Drug: Enoxaparin · Other: Placebo

Interventions

  • Andexanet alfa will be administered as an intravenous bolus followed by an infusion, however, in Module 3, only a bolus will be given.

  • Rivaroxaban will be administered as an oral tablet.

  • Apixaban will be administered as an oral tablet.

  • Enoxaparin will be administered as a subcutaneous injection.

  • OtherPlacebo

    Placebo will replace andexanet and be given as an IV bolus plus infusion in Modules 1 and 2; in Module 3, placebo will be IV bolus only. In Module 4, an oral placebo tablet will replace rivaroxaban and apixaban.

06

What researchers measure

Primary outcomes

  1. Anti-Factor (F) Xa activity

    To determine the pharmacodynamic (PD) effect of andexanet doses by assessing reversal of rivaroxaban or apixaban anticoagulation measured by chromogenic enzymatic anti-FXa activity assays.

    Time frame: Day 1 post dose

  2. Change from baseline in anti-FXa activity

    To determine the PD effect of andexanet doses by assessing reversal of rivaroxaban or apixaban anticoagulation measured by chromogenic enzymatic anti-FXa activity assays.

    Time frame: Day 1 post dose

  3. Thrombin generation potential

    To determine the PD effect of andexanet doses by assessing reversal of rivaroxaban or apixaban anticoagulation measured as thrombin generation potential (including Endogenous Thrombin Potential \[ETP\]).

    Time frame: Day 1 post dose

  4. Change from pre-direct oral anticoagulants (DOAC) in thrombin generation potential

    To determine the PD effect of andexanet doses by assessing reversal of rivaroxaban or apixaban anticoagulation measured as thrombin generation potential (including ETP).

    Time frame: Day 1 post dose

  5. Change from baseline in thrombin generation potential

    To determine the PD effect of andexanet doses by assessing reversal of rivaroxaban or apixaban anticoagulation measured as thrombin generation potential (including ETP).

    Time frame: Day 1 post dose

  6. Time to onset of coagulation

    To determine the PD effect of andexanet doses by assessing reversal of rivaroxaban or apixaban anticoagulation measured as time to onset of coagulation.

    Time frame: Day 1 post dose

  7. Change from pre-DOAC in time to onset of coagulation

    To determine the PD effect of andexanet doses by assessing reversal of rivaroxaban or apixaban anticoagulation measured as time to onset of coagulation.

    Time frame: Day 1 post dose

  8. Change from baseline in time to onset of coagulation

    To determine the PD effect of andexanet doses by assessing reversal of rivaroxaban or apixaban anticoagulation measured as time to onset of coagulation.

    Time frame: Day 1 post dose

  9. Anti-FXa activity following enoxaparin dosing

    To determine anticoagulation by enoxaparin at different time points after andexanet treatment measured by chromogenic enzymatic anti-FXa activity assays.

    Time frame: From Day 1 to Day 2

  10. Thrombin generation potential following enoxaparin dosing

    To determine anticoagulation by enoxaparin at different time points after andexanet treatment measured as thrombin generation potential (including ETP).

    Time frame: From Day 1 to Day 2

Secondary outcomes

  1. Module 3: Anti-FXa activity

    To describe the PD effect of andexanet bolus by assessing reversal of rivaroxaban or apixaban anticoagulation, as measured by chromogenic enzymatic anti-FXa activity assays.

    Time frame: Day 1 post dose

  2. Module 3: Change from baseline in anti-FXa activity

    To describe the PD effect of andexanet bolus by assessing reversal of rivaroxaban or apixaban anticoagulation, as measured by chromogenic enzymatic anti-FXa activity assays.

    Time frame: Day 1 post dose

  3. Module 3: Thrombin generation potential

    To describe the PD effect of andexanet bolus by assessing reversal of rivaroxaban or apixaban anticoagulation, as measured by thrombin generation potential (including ETP).

    Time frame: Day 1 post dose

  4. Module 3: Change from baseline in thrombin generation potential

    To describe the PD effect of andexanet bolus by assessing reversal of rivaroxaban or apixaban anticoagulation, as measured by thrombin generation potential (including ETP).

    Time frame: Day 1 post dose

  5. Module 3: Change from pre-DOAC in thrombin generation potential

    To describe the PD effect of andexanet bolus by assessing reversal of rivaroxaban or apixaban anticoagulation, as measured by thrombin generation potential (including ETP).

    Time frame: Day 1 post dose

  6. Module 3: Time to onset of coagulation

    To describe the PD effect of andexanet bolus by assessing reversal of rivaroxaban or apixaban anticoagulation, as measured by time to onset of coagulation.

    Time frame: Day 1 post dose

  7. Module 3: Change from pre-DOAC in time to onset of coagulation

    To describe the PD effect of andexanet bolus by assessing reversal of rivaroxaban or apixaban anticoagulation, as measured by time to onset of coagulation.

    Time frame: Day 1 post dose

  8. Module 3: Change from baseline in time to onset of coagulation

    To describe the PD effect of andexanet bolus by assessing reversal of rivaroxaban or apixaban anticoagulation, as measured by time to onset of coagulation.

    Time frame: Day 1 post dose

  9. Tissue factor pathway inhibitor (TFPI) activity

    To describe additional PD effects of andexanet doses by assessing reversal of rivaroxaban or apixaban anticoagulation on levels of TFPI activity measured by enzymatic TFPI activity assay.

    Time frame: Up to Day 4

  10. Antithrombin 3 (AT3)

    To describe additional PD effects of andexanet doses by assessing reversal of rivaroxaban or apixaban anticoagulation on levels of AT3 measured by an AT3 enzyme-linked immunosorbent assay (ELISA).

    Time frame: Up to Day 4

  11. Thrombinantithrombin complex (TAT)

    To describe additional PD effects of andexanet doses by assessing reversal of rivaroxaban or apixaban anticoagulation on levels of TAT.

    Time frame: Up to Day 4

  12. Fibrin degradation fragment (D-dimer)

    To describe additional PD effects of andexanet doses by assessing reversal of rivaroxaban or apixaban anticoagulation on levels of D-dimer.

    Time frame: Up to Day 4

  13. Prothrombin fragment 1+2 (F1+2)

    To describe additional PD effects of andexanet doses by assessing reversal of rivaroxaban or apixaban anticoagulation on levels of F1+2.

    Time frame: Up to Day 4

07

Study locations

2 sites
  • Research Site
    Berlin, 14050, Germany
  • Research Site
    Harrow, HA1 3UJ, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2026 to primary completion in Jun 2026, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2025
First posted
Dec 31, 2025
StartActual
Jan 19, 2026
Primary completionActual
Jun 22, 2026
CompletionActual
Jun 22, 2026
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07312851
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Dec 31, 2025
Start date
Jan 19, 2026
Primary completion
Jun 22, 2026
Completion
Jun 22, 2026
Last update
Jul 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: PRT064445 · Rivaroxaban · Apixaban · Enoxaparin

Start the discussion